Volume 16, Number 3, 221-222, DOI: 10.1007/BF02906136

Published in partnership with the

Logo

Association for Immunotherapy of Cancer

Chimeric monoclonal anti-CD20 antibody (rituximab)—an effective treatment for a patient with relapsing hairy cell leukaemia

H Hagberg

View Related Documents

Abstract

A case story is presented, describing a 46 y old man, with a relapsing hairy cell leukaemia. After treatment with monoclonal anti CD-20 antibodies (rituximab) 375 mg/week, four times, a complete remission was obtained which has lasted >9 months. The rituximab treatment produced a better remission than earlier treatments with alpha-interferon and chlorodeoxyadenosine. In addition, in contrast to other treatments, no initial worsening of the pancytopenia was observed.

Keywords  hairy cell leukaemia - anti CD-20 antibodies - rituximab

Fulltext Preview

Image of the first page of the fulltext document